Reported Wednesday, Sep 30 - 8:20am EDT (TheFly subscription required to read more.)

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported sustained positive outcomes from its RESOLVE Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis (EoE) treatment. After 9 months, patients receiving 48mg EP-104GI showed sustained or improved treatment outcomes. Key findings include:- All patients reported reduced symptom severity, with up to 100% reduction and average 65% improvement in SDI scores- 56% reduction in tissue health (EoEHSS Stage) and 45% reduction in Grade score- 77% mean decrease in eosinophil counts with 52% remission rate- One patient maintained complete histologic remission from 3 through 9 monthsThe 6-month data for the 64mg cohort showed up to 86% reduction in symptom severity. The company plans to release additional long-term data with higher doses in Q3 2025.

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dos…

In the phase 1b/2 RESOLVE study, EP-104GI, an injectable formulation of the steroid fluticasone, showed promise in the treatment of eosinophilic esophagitis.

Research Capital analyst André Uddin reiterated his “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals In a Nov. 5 update, Research Capital analyst André Uddin reiterated his “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX), saying the company’s near-term focus remains on advancing its lead candidate EP-104GI in eosinophilic esophagitis while awaiting upcoming clinical readouts.

Analysis Capital analyst Andre Uddin reiterated a “Speculative Purchase” ranking and C$12.00 goal value for Eupraxia Prescribed drugs (Eupraxia Prescribed drugs Inventory Quote, Chart, Information, Analysts, Financials TSX:EPRX) following sturdy early medical information from the corporate’s eosinophilic esophagitis (EoE) program. Victoria, B.C.–based mostly Eupraxia is growing EP-104IAR for osteoarthritis ache and EP-104GI, a brand new fluticasone-based injectable formulation for EoE, a continual inflammatory illness of the esophagus. On Sept. 29, Eupraxia launched preliminary Cohort 9 information from its Section 1b EP-104GI examine, exhibiting a “hanging” Week 4 discount in EoEHSS Grade and Stage scores (–0.40 to –0.50) in contrast with –0.10 to –0.20 in lower-dose teams.

Research Capital analyst Andre Uddin reiterated a “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) following strong early clinical data from the company’s eosinophilic esophagitis (EoE) program. Victoria, B.C.–based Eupraxia is developing EP-104IAR for osteoarthritis pain and EP-104GI, a new fluticasone-based injectable formulation for EoE, a chronic inflammatory disease of the esophagus.

Research Capital analyst André Uddin reiterated his “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals In a Nov. 5 update, Research Capital analyst André Uddin reiterated his “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX), saying the company’s near-term focus remains on advancing its lead candidate EP-104GI in eosinophilic esophagitis while awaiting upcoming clinical readouts.

Research Capital analyst Andre Uddin reiterated a “Speculative Buy” rating and C$12.00 target price for Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) following strong early clinical data from the company’s eosinophilic esophagitis (EoE) program. Victoria, B.C.–based Eupraxia is developing EP-104IAR for osteoarthritis pain and EP-104GI, a new fluticasone-based injectable formulation for EoE, a chronic inflammatory disease of the esophagus.

Analysis Capital analyst Andre Uddin reiterated a “Speculative Purchase” ranking and C$12.00 goal value for Eupraxia Prescribed drugs (Eupraxia Prescribed drugs Inventory Quote, Chart, Information, Analysts, Financials TSX:EPRX) following sturdy early medical information from the corporate’s eosinophilic esophagitis (EoE) program. Victoria, B.C.–based mostly Eupraxia is growing EP-104IAR for osteoarthritis ache and EP-104GI, a brand new fluticasone-based injectable formulation for EoE, a continual inflammatory illness of the esophagus. On Sept. 29, Eupraxia launched preliminary Cohort 9 information from its Section 1b EP-104GI examine, exhibiting a “hanging” Week 4 discount in EoEHSS Grade and Stage scores (–0.40 to –0.50) in contrast with –0.10 to –0.20 in lower-dose teams.

Reported Thursday, Nov 13 - 5:11pm EST (TheFly subscription required to read more.)

Reported Tuesday, Jul 8 - 7:07am EDT (TheFly subscription required to read more.)

Reported Monday, May 5 - 7:18am EDT (TheFly subscription required to read more.)

Reported Tuesday, Feb 25 - 7:06am EST (TheFly subscription required to read more.)

Eupraxia Pharmaceuticals Inc. announces its Q4 2024 financial results highlighting significant advancements in clinical trials and improved financial health.

Eupraxia Pharmaceuticals shares encouraging results from the RESOLVE trial for EP-104GI, indicating significant improvements in treating Eosinophilic Esophagitis symptoms and safety.

Robert Bazemore, Amy Pott and Helen Thackray join Eupraxia’s board as the biotech lines up key upcoming milestones for EP-104GI and its pipeline.

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER,

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data reported by Eupraxia demonstrated a relationship between the number of injections of EP-104GI and

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 24-week symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. Cohort 9 (n=3) showed a mean SDI reduction of 4.0 points at 24 weeks (3 points = clinical remission).Pooled cohorts 4-9 showed clinical remission in 59% at 12 weeks (13/22), 76% at 24 weeks (13/17), and 67% at 52 weeks (6/9). No SAEs reported across 31 patients and >220 patient-months; no oropharyngeal candidiasis observed.

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by leading life science investors Cash

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced positive 1-year clinical results from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The trial demonstrated that 67% of patients in Cohort 5 (48mg dose) maintained clinical remission after 12 months.Key findings include significant tissue health improvements, with patients treated with 4mg per injection showing 47% improvement in grade and 44% in stage at week 36. The drug maintained steady plasma levels through 52 weeks, below typical asthma inhaler levels. Importantly, no serious adverse events or oral/gastrointestinal candidiasis were reported.The company believes EP-104GI could potentially offer a revolutionary once-yearly treatment option, administered during routine annual endoscopy procedures, presenting a significant advantage over current daily oral steroids or weekly biologics.